Anika Therapeutics (ANIK) Cash & Equivalents (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Cash & Equivalents data on file, last reported at $41.0 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $41.0 million, down 23.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $41.0 million (down 23.14% YoY), and the FY2025 annual result was $57.5 million, up 3.33% from the prior year.
• Cash & Equivalents retreated to $41.0 million in Q1 2026 per ANIK's latest filing, from $57.5 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $91.4 million in Q2 2022 and troughed at $41.0 million in Q1 2026.
• A 5-year average of $67.8 million and a median of $65.1 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents declined 28.8% in 2023, then gained 3.33% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $86.3 million in 2022, then retreated by 20.37% to $68.7 million in 2023, then retreated by 19.07% to $55.6 million in 2024, then increased by 3.33% to $57.5 million in 2025, then dropped by 28.64% to $41.0 million in 2026.
• Business Quant data shows ANIK's Cash & Equivalents at $41.0 million in Q1 2026, $57.5 million in Q4 2025, and $58.0 million in Q3 2025.